Exelixis | EXEL - Umlaufvermögen

Aktienkurs
44.29
Täglich Wechseln
-1.57 -3.42%
Monatlich
7.84%
Jährlich
22.52%
Q2 Prognose
43.06




Umlaufvermögen Veränderung Datum
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agios Pharmaceuticals USD 942.05M 91.06M 2025-12
Akebia Therapeutics USD 252.96M 5.38M 2025-12
Amgen USD 29.06B 1.17B 2025-12
AstraZeneca USD 28.72B 1.22B 2025-12
Bayer EUR 32.91B 30M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Cytokinetics USD 916.97M 60.37M 2025-12
Eisai JPY 840.88B 50.18B 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Exelixis USD 1.44B 41.03M 2025-12
Genmab DKK 2.88B 1.59B 2025-12
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Incyte USD 5.02B 746.01M 2025-12
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
Merck USD 47.56B 10.49B 2025-09
Moderna USD 6.54B 54M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 46.92B 3.22B 2025-09
Puma Biotechnology USD 143.58M 7M 2025-09
Sanofi EUR 30.95B 8.99B 2025-12
Takeda JPY 3.12T 195.82B 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Xencor USD 599.82M 81.38M 2025-12